Treatment Resistance: Understanding the Layers
How cancer survives, adapts and changes—and why understanding resistance is essential.
When cancer progresses, it is natural to ask:
Why did treatment stop working?
Was something already resistant?
Has the cancer changed?
Is there another vulnerability we have not yet understood?
This hub brings together research on the overlapping mechanisms that can help cancer survive treatment. It connects those mechanisms with the wider picture: tumour characteristics, molecular findings, treatment history, drug exposure and the person living with the cancer.
The central idea is layering: adding connected layers of understanding to the map we already have—not simply adding more medicines or supplements to a treatment plan.
Resistance can involve several interacting processes, and their importance can change over time.
Understanding those relationships helps us ask more useful questions about what might matter now.
Explore the hub
Start with the overview that best matches your question, or follow the mechanism pages in order.
Each page explores one part of the picture; none should be read as a complete explanation of an individual person’s resistance.
Page 4. Some cancer cells pump drugs out
Drug-efflux transporters, multi-drug resistance and why blocking a cancer-cell pump is not a simple or universally safe solution.
Page 5. Some cells avoid self-destruction
Apoptosis, survival signalling and why damaging a cancer cell does not always lead to its death.
Page 6. The major shift: CSCs are plastic
Why stem-like behaviour can be a changing cell state rather than a permanent identity—and how that changes the resistance picture.
Page 7. The tumour is an ecosystem
How blood vessels, oxygen supply, immune cells, fibroblasts and surrounding tissue can influence treatment response.
Page 8. Cancer’s changing fuel systems: making sense of metabolic approaches
Metabolic flexibility, alternative fuel pathways and the evidence behind proposed metabolic interventions.
Page 9. Beyond “boosting immunity”: cancer stem cells and immunotherapy resistance
Immune recognition, tumour access, suppressive signals and the relationship between cell states and immune escape
Connected treatment-resistance pages
Why the layers matter
Many of us begin by learning our cancer type, its receptors, its mutations or the pathways commonly reported as active in that cancer. Those findings matter. But they do not always explain the whole response to treatment.
A pathway map tells us something about the cancer’s signalling. It may not tell us whether a surviving cell is dividing, lying low, repairing damage, exporting a drug, avoiding cell death or receiving protective signals from its surroundings.
This hub adds those layers to the map. It does not replace the information we already have; it helps us understand how that information may fit into a wider, changing system.
1. The cancer’s identity and molecular features
The starting layer for most of us includes learning the diagnosis, tumour characteristics, receptors, biomarkers and relevant molecular findings.
These can help identify the broadest range of standard and integrative treatment options and/or suitable trials.
CSC and resistance research adds context to the information we gather. It not does replace clinically validated testing or cancer-specific evidence.
2. The cancer cells’ current behaviour
Cells within the same tumour are not necessarily behaving in the same way.
Some may be actively growing, while others are slow-cycling or in more treatment-tolerant states.
Some cells may shave already strengthened damage repair, increased drug export or resisted the signals that would normally trigger cell death. Research shows us that these mechanisms can overlap within the same surviving population.
3. The surroundings supporting those cells
Cancer cells do not live in isolation.
Their local environment can affect oxygen and nutrient supply, drug penetration, immune-cell access and the signals they receive.
A treatment may be active against one cancer cell while the surrounding tissue around another lesion still helps protect that cell or supports adaptation.
4. Treatment under-exposure
Does enough active medicine reach—and remain inside—the cancer cells?
This layer connects two related but distinct questions: how the person’s body processes a medicine, and what happens to that medicine once it reaches a cancer cell.
Drug metabolism and drug–supplement interactions belong to the first question: could they change how much active treatment is available to reach the tumour? Cancer-cell efflux pumps belong to the second: could the cells pump some medicines back out, reducing the amount that remains inside them?
Having some grasp of both helps us understand why treatment exposure is a layer of the resistance picture—not simply a question of which drug was chosen. It is particularly relevant when reviewing a chemotherapy-heavy regimen, moving between treatments, or discussing medicines and supplements with the oncology team.
5. The person carrying the treatment load
The resistance map is incomplete without the person living through treatment. We are not just looking for a vulnerability in the cancer; we are also asking what it takes for someone to receive treatment, recover between doses and keep living a life that matters to them.
This layer brings treatment tolerance, side effects, nutrition, strength, daily functioning and personal priorities into the same conversation as tumour biology. What has previous treatment already demanded of this person? What are they managing now? What might another treatment add—not only in potential benefit, but in burden?
Keeping these layers connected means taking both the cancer and the person seriously.
6. The strength of the evidence
Every proposed intervention needs its own evidence layer.
A mechanism observed in a cell dish is not the same as a treatment shown to improve outcomes in people. Animal studies, patient-tissue findings, early clinical studies and controlled trials answer different questions.
The useful questions are not only “Does this affect a pathway?” but also “Does that pathway matter in this cancer alongside my current approach, can the intervention reach it safely, and has meaningful benefit been demonstrated in people?”
The layers interact—they are not separate boxes
Imagine a cancer cell in a low-oxygen region of a tumour. It may slow its division, alter its metabolism, use autophagy to recycle internal components and receive protective signals from nearby cells. Its state may also influence how readily it responds to treatment or immune attack.
That one example connects several pages in this hub: lying low, metabolic flexibility, cellular recycling, plasticity and the tumour ecosystem.
These are not necessarily competing explanations. Several may work together. Their relative importance can also change as treatment and local conditions change.
That is why reading about one mechanism can be useful—but treating it as the whole answer can be misleading.
Why cancer stem cells are part of this picture
The word “stem” refers to abilities associated with stem cells, particularly renewing their own population and producing cells with different characteristics. The term “cancer stem cell” describes those functional abilities; it does not necessarily identify the cell in which the cancer originally began.
The name can make CSCs sound like a permanently separate group of “master cells.” The picture explored in this hub is more dynamic. In some cancers, cells can gain or lose stem-like properties as their surroundings and treatment pressures change. Researchers call this capacity to change state cellular plasticity.
This matters because resistance is not always about finding one hidden cell population or one new mutation. It may also involve understanding what allows cells to enter, maintain or leave a treatment-tolerant state.
CSC-like states are one part of resistance biology—not a universal explanation for every cancer that progresses.
Layering understanding is not the same as stacking treatments
The idea of overlapping survival routes helps explain the appeal of complex integrative protocols: if cancer has several escape routes, blocking several at once can sound logical.
But a biologically plausible combination is not automatically an effective or safe combination.
A collection of medicines or supplements does not become a validated resistance strategy because each ingredient affects a pathway in laboratory research. The relevant questions include whether the proposed targets matter in the current cancer, whether effective concentrations are achievable, whether the components interact, and whether the combination has demonstrated benefit in people.
This hub therefore supports layered reasoning—not a checklist of everything to block.
The aim is to understand which mechanisms may be relevant, distinguish what is known from what remains experimental, and connect that understanding with evidence-based treatment discussions.
What progression does—and does not—tell us
Progression tells us that the cancer is growing despite the current treatment approach. It does not, by itself, identify which resistance mechanism is responsible.
It also does not erase the value of an earlier response. A treatment may have reduced tumour burden, relieved symptoms or provided meaningful disease control even if surviving cells later contribute to renewed growth.
Depending on the cancer type, previous testing and treatment history, progression may be a point at which the team considers whether further molecular testing, a biopsy, a treatment-specific resistance review or clinical-trial assessment would be useful. None guarantees a new option, and not every person needs repeat testing.
Ways to use this hub
1. Start with your question.
Choose the page closest to what you are trying to understand: dormancy or slow-growing survivors, drug exposure, DNA repair, immune escape or another resistance mechanism.
2. Follow the connections.
Read all the pages in the hub (including any of the connected pages) to see how that mechanism overlaps with cell-state changes, metabolism and the tumour environment.
3. Keep your cancer’s clinical context alongside the research.
Use disease-specific and biomarker-specific notes and study support pages when the question depends on a particular diagnosis, molecular finding or treatment.
4. Check the evidence before drawing a treatment conclusion.
Separate mechanistic findings from demonstrated clinical benefit.
5. Bring the connected questions into your care discussions.
The hub is intended to support understanding and conversation—not to diagnose the cause of resistance from a scan or select a personal treatment protocol.
Questions this broader map can help us ask
What is known about resistance to my current treatment in my cancer type?
Which findings are clinically actionable now, and which remain research observations?
Could my cancer have changed in a way that makes further testing useful?
Does a proposed combination address a demonstrated vulnerability, or only a theoretical one?
Could a medicine or supplement alter treatment exposure or add toxicity?
How do the likely benefits and burdens fit my treatment capacity and priorities?
Are there relevant trials that match my cancer’s current biology and treatment history?
About the research behind this hub
The cancer-stem-cell pages draw on the review Cancer stem cells and drug resistance in cancer: molecular mechanisms and therapeutic targets, by Hamdy and colleagues, published in Molecular Biomedicine in July 2026, alongside supporting research discussed on the individual pages.
It is a review article, not a clinical trial. It brings previously published findings together to examine resistance mechanisms and possible therapeutic targets. It does not establish that every mechanism applies to every cancer or that every proposed intervention benefits patients.
The purpose of this free study-support hub is to put that research into context: another layer on the map we use to understand current treatment, previous responses and options under consideration.
A note from the hub’s creator
As a health advocate living with cancer since 2014 I have navigated multiple treatments and understand that the biology is only one part of the experience. I am alive, but like s many here live with endless treatment decisions, side effects, uncertainty, practical demands and the need to protect my quality of life.
Each person I have met in my group brings a different experience with cancer, variation in treatment history, and their responses and priorities always differ greatly.
My aim with this free study-support community hub is to keep those layers connected—without pretending that a research paper can tell us exactly what is happening in one person, or that a longer list of interventions is necessarily a better plan.
This information is for education only. It is not medical advice, diagnosis or treatment. Please speak with a qualified clinician before making changes to care, medication or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
About Abbey
References and further reading
The anchor review and supporting publications below are drawn from the supplied hub pages. Each entry includes the publication title, year and URL. The individual mechanism pages provide more detailed study-specific reading.
Cancer stem cells and drug resistance in cancer: molecular mechanisms and therapeutic targets (2026).
https://doi.org/10.1186/s43556-026-00516-2
Cancer stem cells: landscape, challenges and emerging therapeutic innovations (2025).
https://doi.org/10.1038/s41392-025-02360-2
Update on epithelial-mesenchymal plasticity in cancer progression (2024).
https://doi.org/10.1146/annurev-pathmechdis-051222-122423
Tumor cell plasticity in targeted therapy-induced resistance: current knowledge and future perspectives (2023).
https://www.nature.com/articles/s41392-023-01383-x
Dormancy, stemness, and therapy resistance: interconnected players in tumor evolution (2023).
https://pmc.ncbi.nlm.nih.gov/articles/PMC10014678/
A cell cycle centric view of tumour dormancy (2023).
https://www.nature.com/articles/s41416-023-02401-z
Autophagy and Cancer Dormancy (2021).
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.627023/full
Senescence in cancer (2025).
https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00224-7
Tumor microenvironment as niche constructed by cancer stem cells: Breaking the ecosystem to combat cancer (2025).
https://doi.org/10.1016/j.jare.2024.06.014
Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming (2025).
https://doi.org/10.3389/fphar.2025.1634413
Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review (2025).
https://doi.org/10.1038/s41420-025-02566-x
Cancer stem cell mimicry for immune evasion and therapeutic resistance (2024).
https://doi.org/10.1016/j.stem.2024.06.003
Stemness in solid malignancies: coping with immune attack (2024).
https://www.nature.com/articles/s41568-024-00760-0
Cancer stem cells and niches: challenges in immunotherapy resistance (2025).
https://doi.org/10.1186/s12943-025-02265-2
Reversal of Multi-drug Resistance in Cancer by Multi-Functional Flavonoids (2019).
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00487/full
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (2017).
https://www.nejm.org/doi/full/10.1056/NEJMoa1706450
Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade (2017).
https://www.science.org/doi/10.1126/science.aan6733
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (2020).
https://www.nejm.org/doi/full/10.1056/NEJMoa2012971